AP NEWS

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H1 2018 - ResearchAndMarkets.com

June 6, 2018

DUBLIN--(BUSINESS WIRE)--Jun 6, 2018--The “Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) pipeline target constitutes close to 28 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 9, 3, 11 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

The report outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

Key Topics Covered

Introduction Report Coverage Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Overview Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type

Companies Mentioned

AB Science SA Almirall SA Archer Pharmaceuticals Inc Asana BioSciences LLC Beijing Hanmi Pharmaceutical Co Ltd Celgene Corp Clevexel Pharma SAS Fujifilm Holdings Corporation Genosco Inc Gilead Sciences Inc GlaxoSmithKline Plc Hutchison MediPharma Ltd Japan Tobacco Inc Levolta Pharmaceuticals Inc Merck KGaA Millennium Pharmaceuticals Inc Portola Pharmaceuticals Inc Rigel Pharmaceuticals Inc Taiho Pharmaceutical Co Ltd TopiVert Ltd

For more information about this report visit https://www.researchandmarkets.com/research/8tt5tn/tyrosine_protein?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180606005503/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs ,Enzymes

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/06/2018 04:47 AM/DISC: 06/06/2018 04:47 AM

http://www.businesswire.com/news/home/20180606005503/en

AP RADIO
Update hourly